Summary of allocation of fair value of assets acquired and liabilities assumed (Detail) (USD $)	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2012	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2012 Novozymes Biopharma Sweden Ab	Dec. 20, 2011 Novozymes Biopharma Sweden Ab
Business Acquisition [Line Items]
Accounts receivable					$ 5,088,000
Inventory					10,497,000
Prepaid expenses					180,000
Fixed assets					9,089,000
Customer relationships and acquired technology					6,705,000
Deferred tax liability					(198,000)
Accounts payable and other liabilities assumed					(2,563,000)
Net assets acquired					28,798,000
Less total consideration transferred					(28,056,000)	(28,495,000)
Gain on bargain purchase	$ 314,000	$ 427,000	$ 427,478	$ 314,244	$ 742,000